Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Rendell

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Expert Opinion on Pharmacotherapy|August 5, 2021
Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetesMarc S Rendell
Expert Review of Endocrinology & Metabolism|November 1, 2018
Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetesMarc S Rendell
Drug Design, Development and Therapy|March 19, 2019
The journey from gene knockout to clinical medicine: telotristat and sotagliflozinMarc S Rendell
Expert Opinion on Drug Safety|July 6, 2017
The safety of albiglutide for the treatment of type 2 diabetesMarc S Rendell
Expert Opinion on Pharmacotherapy|December 8, 2017
Efficacy and safety of sotagliflozin in treating diabetes type 1Marc S Rendell
Expert Opinion on Biological Therapy|September 29, 2016
Albiglutide: a unique GLP-1 receptor agonistMarc S Rendell
Expert Review of Endocrinology & Metabolism|August 1, 2018
Albiglutide for the management of type 2 diabetesMarc S Rendell
Expert Opinion on Investigational Drugs|January 11, 2021
The time to develop treatments for diabetic neuropathyMarc S Rendell
Diabetes, Obesity & Metabolism|July 24, 2019
Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocolMarc S Rendell
Expert Review of Endocrinology & Metabolism|January 30, 2023
Obesity and diabetes: the final frontierMarc S Rendell
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Expert Opinion on Pharmacotherapy|August 5, 2021
Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetesMarc S Rendell
Expert Review of Endocrinology & Metabolism|November 1, 2018
Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetesMarc S Rendell
Drug Design, Development and Therapy|March 19, 2019
The journey from gene knockout to clinical medicine: telotristat and sotagliflozinMarc S Rendell
Expert Opinion on Drug Safety|July 6, 2017
The safety of albiglutide for the treatment of type 2 diabetesMarc S Rendell
Expert Opinion on Pharmacotherapy|December 8, 2017
Efficacy and safety of sotagliflozin in treating diabetes type 1Marc S Rendell
Expert Opinion on Biological Therapy|September 29, 2016
Albiglutide: a unique GLP-1 receptor agonistMarc S Rendell
Expert Review of Endocrinology & Metabolism|August 1, 2018
Albiglutide for the management of type 2 diabetesMarc S Rendell
Expert Opinion on Investigational Drugs|January 11, 2021
The time to develop treatments for diabetic neuropathyMarc S Rendell
Diabetes, Obesity & Metabolism|July 24, 2019
Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocolMarc S Rendell
Expert Review of Endocrinology & Metabolism|January 30, 2023
Obesity and diabetes: the final frontierMarc S Rendell
Pageof 3